Workflow
Cidara Therapeutics, Inc. (CDTX) Accelerates Phase 3 Trial for Single-Dose Flu Antiviral CD388

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Cidara Therapeutics, Inc. is one of them. Cidara Therapeutics, Inc. (NASDAQ:CDTX) is a biotechnology company leveraging its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics. Its lead candidate, CD388, is a long-acting antiviral designed to provide universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral replication. In September 2025, CDT ...